Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEO-FORCE: necitumumab plus osimertinib for EGFR-mutated advanced non-small cell lung cancer
jRCT2021210079Phase 2Active, not recruiting
- Sponsor
- Nippon Kayaku Co., Ltd.
- Start
- Sep 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of necitumumab and osimertinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Nippon Kayaku Co., Ltd. Primary endpoints: Dose-limiting toxicity, Maximum tolerated dose and 2 more. Started Sep 2022; status: active, not recruiting.
02
Drugs
necitumumabosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2021210079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021210079.